Roivant Sciences ROIV
NASDAQ ROIV
$34.99 +0.58 (+1.67%)
As of: Sep 4, 2026 · 3:22 PM EDT

Roivant Sciences (ROIV) Prepaid Assets (2021 - 2026)

Roivant Sciences' (ROIV) quarterly Prepaid Assets came in at $105.3 million in Q1 2026, down 6.94% YoY from $113.2 million in Q1 2025, and down 18.93% on a QoQ basis from $129.9 million in Q4 2025.

Analysis

Roivant Sciences (ROIV) Prepaid Assets (2021 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has 6 years of Prepaid Assets data on file, last reported at $105.3 million in Q1 2026.

  • Quarterly Prepaid Assets fell 6.94% year-over-year to $105.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (down 6.94% YoY) and the FY2026 annual result came in at $105.3 million, down 6.94% from the prior year.
  • Prepaid Assets eased to $105.3 million in Q1 2026, from $129.9 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $323.0 million in Q2 2024 to a low of $53.4 million in Q1 2022.
  • A 5-year average of $103.1 million and a median of $93.3 million in 2022 frame the typical range for Prepaid Assets.
  • Annual changes were most pronounced in 2024 — Prepaid Assets soared 399.53% — and 2025, when it tumbled 65.14%.
  • Tracing ROIV's Prepaid Assets over 5 years: stood at $69.5 million in 2022, then soared by 95.55% to $135.9 million in 2023, then plunged by 57.58% to $57.7 million in 2024, then jumped by 125.32% to $129.9 million in 2025, then decreased by 18.93% to $105.3 million in 2026.
  • The last three Prepaid Assets figures came in at $105.3 million (Q1 2026), $129.9 million (Q4 2025), and $125.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn
10 Roivant Sciences 25.21 Bn 25.21 Bn 1.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 128.37 Mn
Mar 31, 2026 105.32 Mn
Dec 31, 2025 129.91 Mn
Sep 30, 2025 125.81 Mn
Jun 30, 2025 112.60 Mn
Mar 31, 2025 113.17 Mn
Dec 31, 2024 217.46 Mn
Sep 30, 2024 94.23 Mn
Jun 30, 2024 322.99 Mn
Mar 31, 2024 80.61 Mn
Dec 31, 2023 135.92 Mn
Sep 30, 2023 143.40 Mn
Jun 30, 2023 127.07 Mn
Mar 31, 2023 121.77 Mn
Dec 31, 2022 118.80 Mn
Sep 30, 2022 111.85 Mn
Jun 30, 2022 93.27 Mn
Mar 31, 2022 86.12 Mn
Dec 31, 2021 70.33 Mn
Sep 30, 2021 55.56 Mn